Recent advances in biomimetic nanodelivery systems: New brain-targeting strategies

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 358, P. 439 - 464

Published: May 13, 2023

Language: Английский

---

Emergence and impact of theranostic‐nanoformulation of triple therapeutics for combination cancer therapy

Smart Medicine, Journal Year: 2024, Volume and Issue: 3(1)

Published: Jan. 30, 2024

Cancer remains a major global health threat necessitating the multipronged approaches for its prevention and management. Traditional in form of chemotherapy, surgery, radiotherapy are often encountered with poor patient outcomes evidenced by high mortality morbidity, compelling need precision medicine cancer patients to enable personalized targeted treatment. There has been an emergence smart multimodal theranostic nanoformulation triple combination therapy last few years, which dramatically enhances overall safety vivo potential clinical applications minimal toxicity. However, it is imperative gain insight into limitations this system terms translation, cost-effectiveness, accessibility, multidisciplinary collaboration. This review paper aims highlight compare impact recent nanoformulations therapeutics single nanocarrier effective management provide new dimension diagnostic treatment simultaneously.

Language: Английский

---

In situ cellular hitchhiking of nanoparticles for drug delivery

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 204, P. 115143 - 115143

Published: Nov. 24, 2023

Language: Английский

---

Emerging delivery approaches for targeted pulmonary fibrosis treatment

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 204, P. 115147 - 115147

Published: Dec. 6, 2023

Language: Английский

---

Macrophages as Promising Carriers for Nanoparticle Delivery in Anticancer Therapy

International Journal of Nanomedicine, Journal Year: 2023, Volume and Issue: Volume 18, P. 4521 - 4539

Published: Aug. 1, 2023

Abstract: Macrophages play a critical role in the immune response due to their ability recognize and remove pathogens, as well present antigens, which are involved inflammation, but they also one of most abundant cell populations tumor microenvironment. In recent years, macrophages have become promising cellular carriers for drug nanoparticle delivery microenvironment, mainly natural properties such biocompatibility, degradability, lack immunogenicity, long half-life circulation, crossing biological barriers, possibility migration accumulation at site inflammation tumor. For effectiveness this therapeutic strategy, known "Trojan horse", it is important that nanoparticles engulfed by do not affect proper functioning. our review, we discussed how size, shape, chemical mechanical influence internalization macrophages. addition, described research utilizing macrophages, membranes macrophage-derived exosomes anticancer therapy. As prospect wider use postulate its future application boron environment neutron capture Keywords: carriers, therapy, therapy

Language: Английский

---

Convergence of nanomedicine and neutrophils for drug delivery

Bioactive Materials, Journal Year: 2024, Volume and Issue: 35, P. 150 - 166

Published: Jan. 27, 2024

Neutrophils have recently emerged as promising carriers for drug delivery due to their unique properties including rapid response toward inflammation, chemotaxis, and transmigration. When integrated with nanotechnology that has enormous advantages in improving treatment efficacy reducing side effects, neutrophil-based nano-drug systems expanded the repertoire of nanoparticles employed precise therapeutic interventions by either coating membranes, loading inside living cells, or engineering chimeric antigen receptor (CAR)-neutrophils. These neutrophil-inspired therapies shown superior biocompatibility, targeting ability, robustness. In this review, we summarized benefits combining neutrophils nanotechnologies, design principles underlying mechanisms, various applications disease treatments. The challenges prospects were also discussed.

Language: Английский

---

Cell-mediated nanoparticle delivery systems: towards precision nanomedicine

Drug Delivery and Translational Research, Journal Year: 2024, Volume and Issue: 14(11), P. 3032 - 3054

Published: April 13, 2024

Cell-mediated nanoparticle delivery systems (CMNDDs) utilize cells as carriers to deliver the drug-loaded nanoparticles. Unlike traditional drug approaches, CMNDDs take advantages of cell characteristics, such homing capabilities stem cells, inflammatory chemotaxis neutrophils, prolonged blood circulation red and internalization macrophages. Subsequently, can easily prolong circulation, cross biological barriers, blood-brain barrier bone marrow-blood barrier, rapidly arrive at diseased areas. Such advantageous properties make promising candidates for precision targeting. In this review, we summarize recent advances in fabrication biomedical applications. Specifically, ligand-receptor interactions, non-covalent covalent are commonly applied constructing vitro. By hitchhiking macrophages, monocytes, platelets, nanoparticles be internalized or attached construct vivo. Then highlight application treating different diseases, cancer, central nervous system disorders, lung cardiovascular with a brief discussion about challenges future perspectives end.

Language: Английский

---

Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(14)

Published: Dec. 17, 2023

The success of personalized medicine in oncology relies on using highly effective and precise therapeutic modalities such as small interfering RNA (siRNA) monoclonal antibodies (mAbs). Unfortunately, the clinical exploitation these biological drugs has encountered obstacles overcoming intricate barriers. Drug delivery technologies represent a plausible strategy to overcome barriers, ultimately facilitating access intracellular domains. Here, an overview current landscape how nanotechnology dealt with protein corona phenomena first determinant barrier is presented. This continues analysis strategies tumor, along conceivable methods for enhanced tumor penetration. As final step, cellular barriers that nanocarriers must confront order their cargo reach target are deeply analyzed. review concludes critical future perspectives translational advances oncological nanomedicine.

Language: Английский

---

Macrophage-related therapeutic strategies: Regulation of phenotypic switching and construction of drug delivery systems

Pharmacological Research, Journal Year: 2023, Volume and Issue: 199, P. 107022 - 107022

Published: Dec. 1, 2023

Macrophages, as highly phenotypic plastic immune cells, play diverse roles in different pathological conditions. Changing and controlling the phenotypes of macrophages is considered a novel potential therapeutic intervention. Meanwhile, specific transmembrane proteins anchoring on surface macrophage membrane are relatively conserved, supporting its functional properties, such inflammatory chemotaxis tumor targeting. Thus, series drug delivery systems related to commonly used treat chronic diseases. This review summarizes macrophages-based strategies for diseases, discusses regulation their polarization processes, presents how design apply site-specific targeted vivo based derived receptors. It aims provide better understanding immunoregulation proposes approaches

Language: Английский

---

Fabrication of TPGS decorated Etravirine loaded lipidic nanocarriers as a neoteric oral bioavailability enhancer for lymphatic targeting

Discover Nano, Journal Year: 2024, Volume and Issue: 19(1)

Published: Jan. 4, 2024

Abstract Etravirine (ERVN) is a potential NNRTI (non-nucleoside reverse transcriptase inhibitor) in treating HIV infection. It possesses extremely low oral bioavailability. The present research aims to optimize the formulation and characterization of TPGS-enriched ERVN-loaded lipid-based nanocarriers (NLCs) for HIV-infected patients. formulation, ERVN–TPGS–NLCs, was optimized by central composite rotational design using modified-solvent emulsification process. Various parameters NLCs were evaluated, including globule size 121.56 ± 2.174 nm, PDI 0.172 0.042, zeta − 7.32 0.021 mV, %EE 94.42 8.65% ERVN %DL 8.94 0.759% spherical shape revealed TEM. PXRD also performed identify crystallinity sample. In-vitro drug release showed % cumulative 83.72 8.35% at pH 1.2 90.61 9.11% 6.8, respectively, whereas from suspension (ERVN-S) found be 21.13 2.01% 24.84 2.51 6.8 end 48 h. Further, intestinal permeation study confocal microscope approximately three-fold two-fold increased ERVN–TPGS–NLCs ERVN-NLCs across gut sac compared ERVN-S. Hemolysis compatibility lipolysis studies predict in-vivo fate formulation. pharmacokinetic 3.13-fold increment relative bioavailability, which agrees with ex-vivo studies, lymphatic uptake validated cycloheximide along designed impact AUC. This ensures that take minimize first-pass metabolism followed improved bioavailability ERVN. Thus, enhanced can reduce high dose adverse effects related dose-related burden. Graphical abstract

Language: Английский

---